




MRI OF FOCAL LIVER LESIONS: NON-CIRRHOTIC LIVER



Kartik S Jhaveri, MD
Director, Abdominal MRI
Director, CME program

LESION CHARACTERIZATION –CT VS MR



MULTIFOCAL NODULAR FAT INFILTRATION

OVERVIEW

Why Liver MR ?

Liver MR Techniques: Old & New

Liver Specific MR Contrast


MR Interpretation Algorithm

Review of Common Focal liver Lesions

Conclusion


2

OPTIMAL MR PROTOCOL










5

LESION DETECTION -CT VS MR




STANDARD LIVER PROTOCOL





OPTIMAL ARTERIAL PHASE



TOO EARLY


OPTIMAL

TIMING CRITICAL !

13


LIVER SPECIFIC CONTRAST AGENTS

PRIMOVIIST (GD-EOB-DTPA)
MULTIHANCE (GD-BOPTA)



DUAL CAPABILITY AGENTS
-DYNAMIC PHASE- LIKE ECCM
-HEPATOCYTE PHASE-BILIARY EXCRETION

DYNAMIC PHASE TIMING




MR FLUORO TRIGGER

IDEAL ART. PHASE TIMING

14

HEPATOBIILIARY PHASE




15-20min


10min Post Injection
Van Kessel CS et al Eur Radiol 2012

17



CONTRAST ENHANCED LIVER MRI



MR INTERPRETATION - BASICS






18




Common Solid Liver Lesions

BENIGN	MALIGNANT
<ul style="list-style-type: none"> Hemangioma Focal Nodular Hyperplasia (FNH) Hepatic Adenoma(HA) 	<ul style="list-style-type: none"> HCC Cholangiocarcinoma Metastasis

20




Focal Nodular Hyperplasia(FNH)




FNH:- Iso on T1 and T2, intense arterial enhancement and no washout. Central scar is a typical feature

FNH - Differential Diagnosis




FNH




26

Hepatocellular Adenoma



Adenoma : Heterogeneous lesion with fat (arrows), arterial enhancement and venous phase iso to mixed signal

FNH- HBP PATTERNS



27

Hepatic Adenoma-Classification

- **HNF1 inactivated (35%):** fatty lesions, low risk for HCC
- **B-catenin activated (10%):** high risk for HCC
- **Inflammatory (50%):** Telangiectatic, risk for HCC, bleeding

30

HNF1 Inactivated (Steatotic) Adenoma

- No liver steatosis
- T2W: homogenous, iso or slightly hyperintense
- Chemical Shift sequences signal dropout
- Art phase; moderate enhancement
- Delayed phase: No persistent enhancement

ADENOMA- HBP PATTERNS

34

INFLAMMATORY ADENOMA

T2 HYPERINTENSE RIM "ATOLL" SIGN

32

FNH VS ADENOMA

- FNH
 1. Strong Arterial Phase Enhancement
 2. Central Scar
 3. Iso or Hyper on HBP

1+3 = Sens 83.8% and Specificity 98.5%
- Adenoma
 1. Lipid/Fat
 2. Mild to Moderate Arterial Phase Enhancement
 3. Hypo on HBP

2+ 3 = Sens 83.7 and Specificity 100%

Grazioli L. Radiology 2012;262:520-29

35

FNH vs Adenoma

LIVER SPECIFIC MR CONTRAST EXAM


*Grazioli L. Radiology 2005; 236:166-77.
 **Giovannoli O. AJR Am J Roentgenol 2008; 190:W290-3.

FIBROLAMELLAR HCC

Fibrolamellar HCC


36

Metastases




T1-Hypo
T2-Intermediate
Art- Hypo, Rim
Portal- Hypo, Rim

SURGICAL PLAN - LOCATION




40

Metastases



Peripheral Washout

Neuroendocrine Tumor



Metastatic Colorectal Carcinoma

Meta-Analysis of Gadoteric Acid Disodium (Gd-EOB-DTPA)-Enhanced Magnetic Resonance Imaging for the Detection of Liver Metastases


Lihua Chen^{1,2*}, Jingyan Zhang³, Lin Zhang⁴, Jing Bao⁵, Chen Liu⁶, Yanbiao Xia⁷, Xunqian Huang^{2,7}, Jian Wang⁸

Table 1. Characteristics of the included studies.


Study	Year	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR	MR
Shimada [20]	2012	25	4	1	28	142	Germany	Iron nanoparticles	angiography	T	1.5T								
Yoshida [11]	2012	23	4	1	28	142	Japan	Iron nanoparticles	angiography	T	1.5T								
Wu [25]	2012	20	3	1	24	120	China	Iron nanoparticles	angiography	T	1.5T								
Lee [10]	2012	20	3	1	24	120	China	Iron nanoparticles	angiography	T	1.5T								
Wang [28]	2011	20	3	1	24	120	China	Iron nanoparticles	angiography	T	1.5T								
Wang [29]	2011	20	3	1	24	120	China	Iron nanoparticles	angiography	T	1.5T								
Wang [30]	2011	20	3	1	24	120	China	Iron nanoparticles	angiography	T	1.5T								
Wang [31]	2011	20	3	1	24	120	China	Iron nanoparticles	angiography	T	1.5T								
Wang [32]	2011	20	3	1	24	120	China	Iron nanoparticles	angiography	T	1.5T								
Wang [33]	2011	20	3	1	24	120	China	Iron nanoparticles	angiography	T	1.5T								
Wang [34]	2011	20	3	1	24	120	China	Iron nanoparticles	angiography	T	1.5T								
Wang [35]	2011	20	3	1	24	120	China	Iron nanoparticles	angiography	T	1.5T								

13 studies
1900 CRLM
Pooled weighted
Sensitivity 93%
Specificity 95%
AUROC 0.98


Hepatobiliary MRI



BILIARY CYSTADENOMA(BCA) / CYSTADENOCA(BCAC)



Cystic Metastases




BILIARY CYSTADENOMA(BCA) / CYSTADENOCA(BCAC)


- Arise from ectopic rests of embryonic cells or peribiliary glands
- Intrahepatic(<10% extrahepatic)
- BCAC de novo or malignant transformation of BCA
- Obstructive jaundice rare and no correlation to malignant change
- **BCAC – Mural nodules ,papillary projections, debris, intrahepatic biliary dilatation**
- **DD- Hyadtid cyst,hemorrhagic cyst,abscess**

44

Cystic Metastases



Biliary Hamartomas



CONCLUSION

- *MR provides Superior Results for Liver Lesion Detection and Characterization vs US and CT*
- *Optimize Liver Protocol performing required Pulse sequences and Contrast Timing Techniques*
- *Follow Basic Rules of Interpretation to avoid Diagnostic Errors*
- *DWI- Detection of focal liver lesions(metastases)*
- *Consider Liver specific MR contrast for FNH vs Adenoma , Preoperative liver metastases staging*

48